Pouget, Jennie G.
Giratallah, Haidy
Langlois, Alec W. R.
El-Boraie, Ahmed
Lerman, Caryn
Knight, Jo http://orcid.org/0000-0002-7148-1660
Cox, Lisa Sanderson
Nollen, Nikki L.
Ahluwalia, Jasjit S.
Benner, Christian
Chenoweth, Meghan J.
Tyndale, Rachel F. http://orcid.org/0000-0003-1297-2053
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (PJY-159710)
Canada Research Chairs
DH | National Institute for Health Research (P20GM130414)
Article History
Received: 2 August 2023
Revised: 14 August 2024
Accepted: 16 August 2024
First Online: 31 August 2024
Competing interests
: The other authors declare no conflicts of interest. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. Ahluwalia received sponsored funds for travel expenses as a speaker for the 2021 and 2022 annual GTNF conference. Dr. Ahluwalia serves as a consultant and has equity in Qnovia, a start-up company developing a prescription nicotine replacement product for FDA approval. At the time of manuscript submission, Dr. El-Boraie was employed by AbbVie Corporation on unrelated topics. Other authors declare that they have no competing interests.
: The clinical trial protocols for KIS-3 and PNAT-2 were approved by institutional review boards at all participating sites and the University of Toronto. Informed consent was obtained from all participants prior to data collection.